An economic analysis of flu vaccination - ILC report
The International Longevity Centre - UK has published a report which presents findings from a new economic model on cost-benefit analyses for differing uptake and efficacy scenarios for the English flu vaccination programme.
Given the rapidly ageing population of the UK and growing pressures on the National Health Service, tackling influenza is an important challenge, especially during the winter months when flu and other related health conditions are most prevalent. Vaccinations are recognised as a crucial defence against flu outbreaks, helping to protect individuals directly and by creating herd immunity. However, all health systems face financial constraints, and understanding the costs and benefits of vaccination comes into consideration by those implementing health policy.
Key findings include:
- Vaccination averts between 180,000 and 626,000 cases of influenza per year in England
- Flu vaccination helps avert between 5,678 and 8,800 premature deaths per year
- The vast majority of hospital cases caused by influenza are among older adults. Over 1,800 individuals hospitalised in 2016-2017 were aged between 80 and 84 - higher than any other age group
- The human capital costs of influenza range from £90 million to £270 million
- The NHS flu vaccination programme costs £50,610 per death averted